Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 356 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prevention of aGVHD Clear all
Completed Not applicable Interventional Results available

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NCT00360685
View directory record Official record
Conditions
Mucositis, Graft-versus-host Disease
Interventions
Tac+MTX, TAC + MMF
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 6, 2026, 10:41 PM EDT
Recruiting Phase 2 Interventional

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury

NCT07016074
View directory record Official record
Conditions
Kidney Injury, Acute
Interventions
Sodium Nitrate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 6, 2026, 10:41 PM EDT
Active, not recruiting Not applicable Interventional

An Early Real-Time Electronic Health Record Risk Algorithm for the Prevention and Treatment of Acute Kidney Injury

NCT03590028
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Early Nephrology Consult (ENC), Standard of Care (SOC)
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 6, 2026, 10:41 PM EDT
Terminated Phase 2Phase 3 Interventional

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

NCT03805789
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
AAT, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation

NCT00803010
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
Tacrolimus (TAC), Methotrexate (MTX), Rapamycin (RAPA)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Phase 2 Interventional

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

NCT01146925
View directory record Official record
Conditions
Contrast-Induced Acute Kidney Injury
Interventions
CRMD-001-Deferiprone, Placebo
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Phase 3 Interventional

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

NCT00473460
View directory record Official record
Conditions
Lung Diseases, Bronchitis, Chronic
Interventions
Avelox (Moxifloxacin, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 6, 2026, 10:41 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

NCT02508194
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
MEDI7510, IIV, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 99 Years
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 6, 2026, 10:41 PM EDT
Recruiting Phase 3 Interventional

Melatonin for Prevention of Kidney Injury

NCT05084196
View directory record Official record
Conditions
Acute Kidney Injury, Adverse Drug Event
Interventions
Melatonin, Placebo Capsule
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 6, 2026, 10:41 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss

NCT00844480
View directory record Official record
Conditions
Bone Loss
Interventions
zoledronic acid, placebo
Drug
Lead sponsor
Thomas J. Schnitzer
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

NCT00795769
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
Interventions
ondansetron, survey administration, management of therapy complications
Drug · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 6, 2026, 10:41 PM EDT
Recruiting Phase 2 Interventional

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

NCT06128070
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate, Multigated Acquisition Scan, Ruxolitinib Phosphate, Tacrolimus
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
2 Years to 22 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 6, 2026, 10:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Postnatal Exercise to Activate Baby's Brown Fat

NCT07467694
View directory record Official record
Conditions
Childhood Obesity Prevention, Childhood Obesity, Physical Activity, Lactation, Breastfeeding, Pregnancy, Exercise
Interventions
Active group
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Not applicable Interventional

GAPcare: The Geriatric Acute & Post-acute Care Coordination Program for Fall Prevention in the Emergency Department

NCT03360305
View directory record Official record
Conditions
Falls (Accidents) in Old Age
Interventions
GAPcare intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
65 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 6, 2026, 10:41 PM EDT
Recruiting Phase 1 Interventional

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

NCT06996119
View directory record Official record
Conditions
Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Emapalumab, Fludarabine, Hematopoietic Cell Transplantation, Melphalan, Multigated Acquisition Scan, Mycophenolate Mofetil, Questionnaire Administration, Tacrolimus
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Phase 1 Interventional

Evaluation of Vitamin D Status in Children With Acute Burns

NCT00536276
View directory record Official record
Conditions
Burns, Bone Demineralization
Interventions
Vitamin D2, Vitamin D3
Dietary Supplement
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
6 Months to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Not applicable Interventional

Lung Protective Ventilation in Pulmonary Thromboendarterectomy (PTE) Patients

NCT00747045
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, Acute Lung Injury
Interventions
Ventilation Strategy
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 6, 2026, 10:41 PM EDT
Not listed Phase 2 Interventional

Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

NCT05764993
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy
Biological · Other
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years to 82 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

NCT03339297
View directory record Official record
Conditions
Graft-versus-host Disease, Acute-graft-versus-host Disease
Interventions
Defibrotide, Standard of Care
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 6, 2026, 10:41 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Nerve Blocks for Episodic Migraine

NCT05734625
View directory record Official record
Conditions
Episodic Migraine
Interventions
Bupivacaine HCl 0.5% Injectable Solution, Methylprednisolone 40 MG Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 6, 2026, 10:41 PM EDT
Recruiting Phase 2 Interventional

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

NCT06904482
View directory record Official record
Conditions
aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions
Haplo-Identical / Cord Blood Transplant
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom

NCT01178840
View directory record Official record
Conditions
Birth Control
Interventions
WC then FC2, FC2 then WC
Device
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 6, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia

NCT00936117
View directory record Official record
Conditions
Leukemia, Fungal Infection
Interventions
Posaconazole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 6, 2026, 10:41 PM EDT